Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematosus

Management of systemic lupus erythematosus and its variable clinical manifestations remain considerable challenges for clinicians and patients. Advances in characterising mechanisms of immune system regulation have been applied to studies of systemic lupus erythematosus, implicating type I interferon and highlighting the contributions of T and B lymphocytes to autoantibody production and tissue damage.1 Despite such progress, the pace of development of more effective therapies for patients has been slow.